Degarelix: a novel gonadotropin-releasing hormone blocker for the treatment of prostate cancer

The efficacy and safety of degarelix: a 12-month, comparative, randomized, open-label, parallel-group phase III study in patients with prostate cancer

(2008) Laurence Klotz et al.   BJU INTERNATIONAL

Cancer Statistics, 2008

(2008) A. Jemal et al.   CA-A CANCER JOURNAL FOR CLINICIANS

Degarelix: A Novel Gonadotropin-Releasing Hormone (GnRH) Receptor Blocker—Results from a 1-yr, Multicentre, Randomised, Phase 2 Dosage-Finding Study in the Treatment of Prostate Cancer

(2008) Hendrik Van Poppel et al.   EUROPEAN UROLOGY

A 1-Year, Open Label, Randomized Phase II Dose Finding Study of Degarelix for the Treatment of Prostate Cancer in North America

(2008) Marc Gittelman et al.   JOURNAL OF UROLOGY

Testosterone Surge: Rationale for Gonadotropin-Releasing Hormone Blockers?

(2008) Hendrik van Poppel et al.   UROLOGY

EAU Guidelines on Prostate Cancer

(2007) Axel Heidenreich et al.   EUROPEAN UROLOGY